+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Cancer Monoclonal Antibodies Market - Growth, Trends, and Forecasts (2020-2025)

  • ID: 4591753
  • Report
  • May 2020
  • Region: Global
  • 115 Pages
  • Mordor Intelligence


  • Amgen Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genmab AS
  • GlaxoSmithKline PLC
  • Johnson & Johnson
The cancer monoclonal antibodies market is expected to witness a CAGR of 9.2% during the forecast period. Certain factors that are driving the market growth include the growing prevalence of cancer, increasing investment in R&D of genomic studies, and rising advancements in and preference toward the specificity of monoclonal antibodies to target cancer.

According to the World Health Organization, cancer is the second leading cause of death worldwide, accounting for an estimated 9.6 million deaths, or one in six deaths, in the year 2018. Lung cancer, prostate cancer, colorectal cancer, and liver cancer are the most common types of cancer in men, while breast cancer, colorectal cancer, lung cancer, cervical cancer and thyroid cancer are the most common among women. The increment in data is expected to provide the basis for any national policy on cancer, leading to an increase in the percentage of people choosing cancer treatment. In the healthcare sector, cancer is one of the biggest concerns. Thus, the increased use of monoclonal antibodies for the treatment of cancer is driving this market.

However, following the regulatory guidelines for monoclonal antibodies related to cancer is a highly rigorous process in most of the regions, globally. The guidelines provide a comprehensive description of the manufacturing processes including quality, good manufacturing practices, process validation, potential for degradation, and the need for stability studies. A stringent regulatory scenario exists globally, such as the US FDA, the European Medicines Agency (EMA), and the Korean FDA. Similar to biologics, biosimilar also faces similar restrictions for getting the approval of monoclonal antibodies in the market. Since it is a time-consuming process, it is considered as one of the major hindering factors for this market. Other factors that restrains the growth of the cancer monoclonal antibodies market are long duration of research and development before clinical trials and the rise in the failures of mAbs in clinical trials.

Key Market Trends

Trastuzumab (Herceptin) is Expected to Hold Significant Market Share in Monoclonal Antibody Therapies

Trastuzumab (Herceptin) is a monoclonal antibody used to treat breast cancer. It is also an approved first-line treatment for HER2+ metastatic cancer of the stomach or gastro-oesophagal junction. According to Roche’s (manufacturer of the drug) annual report 2019, the annual sales revenue generated from the drug Herceptin (oncology) was 69,82 (in million Swiss francs) in 2018 and 60,39 (in million Swiss francs). The country witnessed continued growth, mainly, due to the longer duration of treatment in combination with Perjeta.

However, the common side effects (fever, infection, cough, and rash, among others) and severe side effects (heart failure, allergic reaction, and lung disorders) are associated with the drug. The drug may also result in unnecessary issues for the baby if taken during pregnancy. These side effects may affect the adoption rate and, hence, may act as an inhibiting factor.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

The market is growing at a strong pace in North America. The pharmaceutical and biotechnology firms have gained abundant knowledge and expertise in cancer monoclonal antibodies.

According to the Breast Cancer Organization in 2018, it was estimated that over 2,66,120 cases of invasive breast cancer were diagnosed in women in the United States, along with 63,960 new cases of non-invasive (in situ) breast cancer. With the approval of murine cancer monoclonal antibodies, followed by chimeric and fully human cancer monoclonal antibodies, the sales and the rate of product approvals have increased over the past few years.

Moreover, depending on the high percentage of molecules that are in the pipeline, this scenario may change. Human monoclonal antibody (mAb) is the fastest-growing category in the market. Additionally, with the trend toward developing targeted therapeutics, the focus on fully-humanized cancer monoclonal antibodies is expected to increase, owing to perceived low-level of immunogenicity of these agents. The first human mAb was approved by the United States FDA, in 2002. Since then, many human mAbs have received the FDA approval and few are in the phase-3 studies. Sales of Rituxan (rituximab) grew by 5% in 2015, propelled by the strong demand in the country.

Competitive Landscape

The cancer monoclonal antibodies market is highly consolidated. Some of the companies which are currently dominating the market are Amgen Inc., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Genmab AS, GlaxoSmithKline PLC, Johnson & Johnson, Novartis AG, Seattle Genetics Inc., and Spectrum Pharmaceuticals Inc., among others, hold the substantial market share in the market studied.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.
Note: Product cover images may vary from those shown


  • Amgen Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genmab AS
  • GlaxoSmithKline PLC
  • Johnson & Johnson

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Prevalence of Cancer
4.2.2 Increasing Investment in Research and Development of Genomic Studies
4.2.3 Rising Advancements and Preference toward Specificity of Monoclonal Antibodies to Target Cancer
4.3 Market Restraints
4.3.1 Stringent Regulatory Guidelines
4.3.2 Long Duration of Research and Development with Rising Failures in Clinical Trials
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Types of Monoclonal Antibody
5.1.1 Murine Antibodies
5.1.2 Chimeric Antibodies
5.1.3 Humanized Antibodies
5.2 By Monoclonal Antibody Therapies
5.2.1 Bevacizumab (Avastin)
5.2.2 Rituximab (Rituxan)
5.2.3 Trastuzumab (Herceptin)
5.2.4 Cetuximab (Erbitux)
5.2.5 Panitumumab (Vectibix)
5.2.6 Other Monoclonal Antibody Therapies
5.3 By Application
5.3.1 Breast Cancer
5.3.2 Blood Cancer
5.3.3 Liver Cancer
5.3.4 Brain Cancer
5.3.5 Colorectal Cancer
5.3.6 Other Applications
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South korea Rest of Asia-Pacific
5.4.4 Middle-East & Africa GCC South Africa Rest of Middle-East & Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Amgen Inc.
6.1.2 Bristol Myers Squibb Company
6.1.3 Eli Lilly and Company
6.1.4 F. Hoffmann-La Roche Ltd
6.1.5 Genmab AS
6.1.6 GlaxoSmithKline PLC
6.1.7 Johnson & Johnson
6.1.8 Novartis AG
6.1.9 Merck & Co., Inc
6.1.10 Spectrum Pharmaceuticals Inc.
Note: Product cover images may vary from those shown


A selection of companies mentioned in this report includes:

  • Amgen Inc.
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genmab AS
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Novartis AG
  • Merck & Co., Inc
  • Spectrum Pharmaceuticals Inc.
Note: Product cover images may vary from those shown